• 6 min read
• Published on 29 July 2025
Listen to article
6:42Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Trying to get a big pharmaceutical company to move quickly is often like trying to teach a whale to tap dance. They are colossal, bureaucratic, and weighed down by their own success. Promising new drugs can get lost in the shuffle, starved of oxygen while the company focuses on its existing billion dollar blockbusters. It’s a frustrating reality, but one that, I think, is starting to change.
Look at Bristol Myers Squibb. They’ve just done something rather clever. Instead of letting a promising set of immunology treatments wither on the vine internally, they’ve spun them out into a new venture. And who did they partner with? Bain Capital, a private equity firm not exactly known for its patience. They’ve put $300 million on the table, and you can be sure they’ll want to see a return on that.
To me, this isn't just another corporate deal. It’s a tacit admission that the old model is broken. By handing the reins to a focused, well funded, and frankly, demanding partner, Bristol Myers is giving these potential drugs their best shot at success. It’s like letting your talented child leave home for a specialist school instead of getting lost in the local comprehensive.
So, why all the fuss about immunology? For decades, treatments for autoimmune diseases like rheumatoid arthritis or multiple sclerosis were a bit of a blunt instrument. They carpet bombed the entire immune system, leaving patients vulnerable to all sorts of other nasties. It was a classic case of the cure being almost as bad as the disease.
Modern immunology is far more elegant. It’s about precision. Scientists are now able to target the very specific parts of the immune system that have gone rogue, leaving the rest of it to do its job. Think of it as swapping a sledgehammer for a scalpel. This precision is what makes the field so commercially exciting. A drug that can effectively treat an autoimmune condition without debilitating side effects is, to put it mildly, a potential goldmine.
Now, here is where it gets interesting for those of us watching from the sidelines. The headline deal is just the start. When private equity money floods into a sector, it creates waves. Suddenly, the contract research organisations that run clinical trials and handle regulatory paperwork are in high demand. Their services are essential to getting these new drugs to market quickly, which is exactly what the private equity backers want.
You also have smaller, specialist biotech firms. Companies that have been toiling away on their own immunology platforms could suddenly look like very attractive takeover targets. A successful spin out like the Bristol Myers venture proves the model, and everyone will want a piece of the action. To me, this is the core of the Pharma's Private Equity Pivot: The Immunology Opportunity thesis. It’s not just about one deal, but the entire ecosystem that gets a boost.
Of course, let’s not get carried away. This is still drug development, which is arguably one of the riskiest games in town. Clinical trials fail with depressing regularity, and a promising molecule can turn into a very expensive dud overnight. Private equity’s involvement doesn’t change that fundamental truth. In fact, their relentless focus on speed and returns could even add a different kind of pressure.
Investing in this space requires a strong stomach. It’s not for the faint of heart. But the shift in strategy from the big players is undeniable. They are looking for smarter, more agile ways to innovate, and partnering with private equity seems to be their new favourite trick. For investors who understand the risks, this changing of the guard might just present some compelling possibilities.
View the full Basket:Pharma's Private Equity Pivot: The Immunology Opportunity
View the full Basket:Pharma's Private Equity Pivot: The Immunology Opportunity
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article